Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 5/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | HTR1A | P08908 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 7/20 | 0.53 |
| ▸ | HTR7 | P34969 | 3/20 | 0.53 |
| ▸ | HTR6 | P50406 | 2/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6518624 | 1.00 | ACHE (0.54) | ACHEHTR2CCYP2D6TSHRMAPT | |
| SCHEMBL6518627 | 1.00 | ACHE (0.54) | ACHEHTR2CCYP2D6TSHRMAPT | |
| SCHEMBL16351780 | 0.94 | ADRA1A (0.49) | ACHEHTR2CCYP2D6TSHRMAPT | |
| SCHEMBL16351779 | 0.94 | ADRA1A (0.49) | ACHEHTR2CCYP2D6TSHRMAPT | |
| SCHEMBL16351773 | 0.94 | ADRA1A (0.49) | ACHEHTR2CCYP2D6TSHRMAPT | |
| SCHEMBL6523807 | 0.87 | ACHE (0.71) | ACHEHTR2CCYP2D6TSHRMAPT | |
| SCHEMBL6523805 | 0.87 | ACHE (0.71) | ACHEHTR2CCYP2D6TSHRMAPT | |
| SCHEMBL6523816 | 0.87 | ACHE (0.71) | ACHEHTR2CCYP2D6TSHRMAPT | |
| SCHEMBL6527978 | 0.85 | HTR2A (0.50) | ACHEHTR2CCYP2D6TSHRMAPT | |
| SCHEMBL6527975 | 0.85 | HTR2A (0.50) | ACHEHTR2CCYP2D6TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834555-B2 | Method for treating pain syndrome and other disorders | VM Therapeutics LLC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160318930-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | VM THERAPEUTICS LLC (US) | 2016-11-03 | — | — | US | disclosed |
| US-9402848-B2 | Method for treating pain syndrome and other disorders | VM THERAPEUTICS LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-9402848-B2 | Method for treating pain syndrome and other disorders | VM THERAPEUTICS LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150150875-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | VM DISCOVERY, INC. | 2015-06-04 | — | — | US | disclosed |
| US-20150150875-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | VM DISCOVERY, INC. | 2015-06-04 | — | — | US | disclosed |
| US-8980900-B2 | Method for treating pain syndrome and other disorders | VM Therapeutics, LLC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980900-B2 | Method for treating pain syndrome and other disorders | VM Therapeutics, LLC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140378476-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | VM DISCOVERY, INC. | 2014-12-25 | — | — | US | disclosed |
| US-8865727-B2 | Method for treating pain syndrome and other disorders | VM THERAPEUTICS LLC (US) | 2014-10-21 | — | — | US | disclosed |
| US-20110053960-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | VM DISCOVERY INC. (US) | 2011-03-03 | — | — | US | disclosed |
| CN-101970427-A | Methods of treating pain symptoms and other disorders | VM DISCOVERY INC | 2011-02-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378476-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | CACNA1G, CACNA1H, CACNA1A | ACHE 289/4885HTR2C 981/4885CYP2D6 3702/4885 |
| US-20150150875-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | CACNA1G, CACNA1H, CACNA1A | ACHE 289/4885HTR2C 981/4885CYP2D6 3702/4885 |
| US-20160318930-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | CACNA1G, CACNA1H, CACNA1A | ACHE 289/4885HTR2C 981/4885CYP2D6 3702/4885 |
| US-20110053960-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | CACNA1G, CACNA1H, CACNA1A | ACHE 289/4885HTR2C 981/4885CYP2D6 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.